Literature DB >> 30007825

Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.

Yasuko Hatta1, David Boltz2, Sally Sarawar3, Yoshihiro Kawaoka4, Gabriele Neumann5, Pamuk Bilsel6.   

Abstract

Current influenza vaccines do not provide effective protection against heterologous influenza viruses. The ability of the novel M2SR influenza vaccine to protect against drifted influenza viruses was evaluated in naïve ferrets and in ferrets with pre-existing immunity to influenza. In naïve ferrets, M2SR provided similar protection against drifted challenge viruses as the comparator vaccine, FluMist®. However, in ferrets with pre-existing immunity, M2SR provided superior protection than FluMist in two model systems. In the first model, ferrets were infected with influenza A H1N1pdm and influenza B viruses to mimic the diverse influenza exposure in humans. The pre-infected ferrets, seropositive to H1N1pdm and influenza B but seronegative to H3N2, were then vaccinated with H3N2 M2SR or monovalent H3N2 FluMist virus (A/Brisbane/10/2007, clade 1) and challenged 6 weeks later with a drifted H3N2 virus (clade 3C.2a). Antibody titers to Brisbane/10/2007 were higher in M2SR vaccinated ferrets than in FluMist vaccinated ferrets in the pre-infected ferrets whereas the opposite was observed in naïve ferrets. After challenge with drifted H3N2 virus, M2SR provided superior protection than FluMist monovalent vaccine. In the second model, the impact of homologous pre-existing immunity upon vaccine-induced protection was evaluated. Ferrets, pre-infected with H1N1pdm virus, were vaccinated 90 days later with H1N1pdm M2SR or FluMist monovalent vaccine and challenged 6 weeks later with a pre-pandemic seasonal H1N1 virus, A/Brisbane/59/2007 (Bris59). While cross-reactive serum IgG antibodies against the Bris59 HA were detected after vaccination, anti-Bris59 hemagglutination inhibition antibodies were only detected post-challenge. M2SR provided better protection against Bris59 challenge than FluMist suggesting that homologous pre-existing immunity affected FluMist virus to a greater degree than M2SR. These results suggest that the single replication intranasal M2SR vaccine provides effective protection against drifted influenza A viruses not only in naïve ferrets but also in those with pre-existing immunity in contrast to FluMist viruses.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Drifted; Hemagglutination inhibition; Heterosubtypic immunity; Intranasal; Live influenza; M2-deficient; Pre-existing immunity; Single replication

Mesh:

Substances:

Year:  2018        PMID: 30007825      PMCID: PMC6086587          DOI: 10.1016/j.vaccine.2018.06.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.

Authors:  Suzanne E Ohmit; John C Victor; Judy R Rotthoff; Esther R Teich; Rachel K Truscon; Laura L Baum; Bhavya Rangarajan; Duane W Newton; Matthew L Boulton; Arnold S Monto
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

2.  Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members.

Authors:  Angelia A Eick; Zhong Wang; Hayley Hughes; Stephen M Ford; Steven K Tobler
Journal:  Vaccine       Date:  2009-04-19       Impact factor: 3.641

3.  M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.

Authors:  Yasuko Hatta; David Boltz; Sally Sarawar; Yoshihiro Kawaoka; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2017-06-28       Impact factor: 3.641

4.  Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Authors:  Sanae Sasaki; Maria C Jaimes; Tyson H Holmes; Cornelia L Dekker; Kutubuddin Mahmood; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

5.  Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens.

Authors:  G A Tannock; J A Paul; R D Barry
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

6.  M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.

Authors:  Sally Sarawar; Yasuko Hatta; Shinji Watanabe; Peter Dias; Gabriele Neumann; Yoshihiro Kawaoka; Pamuk Bilsel
Journal:  Vaccine       Date:  2016-09-03       Impact factor: 3.641

7.  Comparative efficacy of inactivated and live attenuated influenza vaccines.

Authors:  Arnold S Monto; Suzanne E Ohmit; Joshua G Petrie; Emileigh Johnson; Rachel Truscon; Esther Teich; Judy Rotthoff; Matthew Boulton; John C Victor
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel.

Authors:  Zhong Wang; Steven Tobler; Jean Roayaei; Angelia Eick
Journal:  JAMA       Date:  2009-03-02       Impact factor: 56.272

9.  2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.

Authors:  Richard K Zimmerman; Mary Patricia Nowalk; Jessie Chung; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Arnold S Monto; Huong Q McLean; Edward A Belongia; Manjusha Gaglani; Kempapura Murthy; Alicia M Fry; Brendan Flannery
Journal:  Clin Infect Dis       Date:  2016-10-04       Impact factor: 20.999

10.  Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines.

Authors:  Xiao-Song He; Tyson H Holmes; Sanae Sasaki; Maria C Jaimes; George W Kemble; Cornelia L Dekker; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

View more
  12 in total

1.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

2.  Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity in vivo.

Authors:  Sweety Samal; Tripti Shrivastava; Praveen Sonkusre; Zaigham Abbas Rizvi; Rajesh Kumar; Shubbir Ahmed; Preeti Vishwakarma; Naveen Yadav; Manish Bansal; Kanchana Chauhan; Sebanta Pokhrel; Supratik Das; Padmakar Tambare; Amit Awasthi
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

Review 3.  The Quest for a Truly Universal Influenza Vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Front Cell Infect Microbiol       Date:  2019-10-10       Impact factor: 5.293

Review 4.  Comparative models for human nasal infections and immunity.

Authors:  Elisa Casadei; Irene Salinas
Journal:  Dev Comp Immunol       Date:  2018-12-01       Impact factor: 3.636

Review 5.  Better influenza vaccines: an industry perspective.

Authors:  Juine-Ruey Chen; Yo-Min Liu; Yung-Chieh Tseng; Che Ma
Journal:  J Biomed Sci       Date:  2020-02-14       Impact factor: 8.410

6.  Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults.

Authors:  Joseph Eiden; Gilad Gordon; Carlos Fierro; Renee Herber; Roger Aitchison; Robert Belshe; Harry Greenberg; Daniel Hoft; Yasuko Hatta; Michael J Moser; Magdalena Tary-Lehmann; Yoshihiro Kawaoka; Gabriele Neumann; Paul Radspinner; Pamuk Bilsel
Journal:  Vaccines (Basel)       Date:  2021-11-24

Review 7.  Animal Models for Influenza Research: Strengths and Weaknesses.

Authors:  Thi-Quyen Nguyen; Rare Rollon; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

Review 8.  The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.

Authors:  Lea Skak Filtenborg Frederiksen; Yibang Zhang; Camilla Foged; Aneesh Thakur
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 9.  M2e-based universal influenza vaccines: a historical overview and new approaches to development.

Authors:  Daria Mezhenskaya; Irina Isakova-Sivak; Larisa Rudenko
Journal:  J Biomed Sci       Date:  2019-10-19       Impact factor: 8.410

10.  A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade.

Authors:  Brigette N Corder; Brianna L Bullard; Gregory A Poland; Eric A Weaver
Journal:  Viruses       Date:  2020-10-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.